WAVE Life Sciences (WVE)
(Delayed Data from NSDQ)
$6.15 USD
-0.12 (-1.91%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $6.14 -0.01 (-0.16%) 7:58 PM ET
4-Sell of 5 4
F Value B Growth D Momentum D VGM
Price, Consensus and EPS Surprise
WVE 6.15 -0.12(-1.91%)
Will WVE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for WVE based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for WVE
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?
WVE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wave Life Sciences (WVE) Soars 8.7%: Is Further Upside Left in the Stock?
Wave Life Sciences (WVE) Reports Q2 Loss, Tops Revenue Estimates
Wave Life Sciences (WVE) Reports Q1 Loss, Lags Revenue Estimates
Other News for WVE
Truist healthcare analyst holds an analyst/industry conference call
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Biotech Alert: Searches spiking for these stocks today
Optimistic Outlook for WVE-003 in Huntington’s Disease: A Buy Rating Reinforced by Promising Clinical Data and Anticipated Regulatory Milestones
Biotech Alert: Searches spiking for these stocks today